Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients
4/28/2014 8:59:56 AM
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study demonstrating conversion from twice-daily tacrolimus to once-daily Envarsus® in stable liver transplant patients in Liver Transplantation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by